Biosante Pharmaceuticals (BPAX)

Add to Watchlists Create an Alert
1.24 +0.09  +7.83%   NASDAQ May 24, 8:00PM BATS Real time Currency in USD

Biosante Pharmaceuticals SG&A Expense Quarterly:

1.949M for March 31, 2013
View Full Chart

Biosante Pharmaceuticals SG&A Expense Quarterly Chart

    Biosante Pharmaceuticals Historical SG&A Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 2   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    March 31, 2013 1.949M
    Dec. 31, 2012 2.902M
    Sept. 30, 2012 1.547M
    June 30, 2012 1.949M
    March 31, 2012 1.832M
    Dec. 31, 2011 1.724M
    Sept. 30, 2011 1.675M
    June 30, 2011 1.989M
    March 31, 2011 1.594M
    Dec. 31, 2010 1.099M
    Sept. 30, 2010 1.534M
    June 30, 2010 1.540M
    March 31, 2010 1.767M
    Dec. 31, 2009 1.630M
    Sept. 30, 2009 1.506M
    June 30, 2009 1.209M
    March 31, 2009 1.029M
    Dec. 31, 2008 1.604M
    Sept. 30, 2008 1.439M
    June 30, 2008 1.593M
    March 31, 2008 Go Pro
    Dec. 31, 2007 Go Pro
    Sept. 30, 2007 Go Pro
    June 30, 2007 Go Pro
    March 31, 2007 Go Pro
       
    Dec. 31, 2006 Go Pro
    Sept. 30, 2006 Go Pro
    June 30, 2006 Go Pro
    March 31, 2006 Go Pro
    Dec. 31, 2005 Go Pro
    Sept. 30, 2005 Go Pro
    June 30, 2005 Go Pro
    March 31, 2005 Go Pro
    Dec. 31, 2004 Go Pro
    Sept. 30, 2004 Go Pro
    June 30, 2004 Go Pro
    March 31, 2004 Go Pro
    Dec. 31, 2003 Go Pro
    Sept. 30, 2003 Go Pro
    June 30, 2003 Go Pro
    March 31, 2003 Go Pro
    Dec. 31, 2002 Go Pro
    Sept. 30, 2002 Go Pro
    June 30, 2002 Go Pro
    March 31, 2002 Go Pro
    Dec. 31, 2001 Go Pro
    Sept. 30, 2001 Go Pro
    June 30, 2001 Go Pro
    March 31, 2001 Go Pro
    Dec. 31, 2000 Go Pro

    About SG&A Expense

    SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

    The details of how SG&A expenses are calculated vary widely from company to company, so YCharts recommends looking at the annual report (10-k) an investor is interested in dissecting this number further.
    Learn More

    Get data for

    BPAX SG&A Expense Quarterly Benchmarks

    Companies
    Repros Therapeutics 1.479M
    Teva Pharmaceutical Industries 1.302B
    Eli Lilly and Company 1.652B

    BPAX SG&A Expense Quarterly Rankings

    Overall 43rd percentile
    4261 of 7600
    Sector 28th percentile
    470 of 653 in Healthcare
    Industry 36th percentile
    151 of 238 in Biotechnology

    BPAX SG&A Expense Quarterly Range, Past 5 Years

    Minimum 1.029M Mar 2009
    Maximum 2.902M Dec 2012
    Average 1.656M